Literature DB >> 27383946

FDA should stand firm on stem-cell treatments.

.   

Abstract

Mesh：

Year:  2016        PMID： 27383946     DOI： 10.1038/535007b

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  3 in total

Review 1.  Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?

Authors:  Kazuo Yano; Alessondra T Speidel; Masayuki Yamato
Journal:  J Tissue Eng Regen Med       Date:  2018-05-21       Impact factor: 3.963

2.  Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation.

Authors:  Sarah Chan
Journal:  Regen Med       Date:  2017-11-09       Impact factor: 3.806

Review 3.  Cell-based therapeutic strategies for multiple sclerosis.

Authors:  Neil J Scolding; Marcelo Pasquini; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2017-11-01       Impact factor: 13.501
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.